What does this research mean for the field?

90Y-NM600 targeted radionuclide therapy improves survival and cure rates in disseminated T-cell Non-Hodgkin's Lymphoma models and induces a durable anti-tumor response that is dependent on the adaptive immune system. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 26, 2019Open Access

90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Y-NM600 treatment was also effective against disseminated tumors, improving survival and cure rates. Finally, we observed a key role for the adaptive immune system in potentiating a durable anti-tumor response to TRT, especially in the presence of microscopic disease.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Hernandez et al. (Tue,) studied this question.

synapsesocial.com/papers/6a0622e3e736c2dea8bdd90d https://doi.org/https://doi.org/10.1038/s42003-019-0327-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Quantitative imaging of 124I and 86Y with PET2011 · 106 citations
2Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues.1969 · 181 citations
3Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer2005 · 1,005 citations
4Treatment of T-cell non-hodgkin’ lymphoma2004 · 34 citations
5Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a90y-labeled immunoconjugate1994 · 23 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo